Pharmaceuticals, Golotta (AbbVie): "13 billion dollars in research and development in 2024"

"Strong commitment to unmet needs in Crohn's and ulcerative colitis patients"

"Our commitment to being a biopharmaceutical company strongly focused on research and innovation has translated into the allocation of approximately 13 billion dollars in research and development in 2024. In the first months of 2025, we have further strengthened our efforts thanks to new partnerships and acquisitions that have strengthened our pipeline." This was stated by Caterina Golotta, medical director of AbbVie Italy, on the first day of the Free2Choose event, organized by the company in Milan and created with the aim of deepening knowledge regarding the main critical issues in the management of chronic inflammatory bowel diseases (MICI-IBD, in English) and exploring new therapeutic opportunities capable of improving the clinical outcomes of patients affected by these diseases.

"Clinical research is only part of our commitment - explains Golotta - since we are also focused on real world evidence, which is a fundamental component to better understand the unmet needs of patients, useful for studying the efficacy and safety of our drugs in clinical practice. Alongside this, we have several collaboration projects with other important interlocutors, such as patient associations. AbbVie - he concludes - is involved in several initiatives to raise awareness and improve knowledge of IBD, but also in communication activities that give patients a voice to promote early diagnosis and also more efficient therapeutic paths".